Research Progress of Adipocytokines in Myocardial Ischemia/Reperfusion Injury
DOI:
https://doi.org/10.53469/jcmp.2024.06(11).23Keywords:
Adipocytokines, Myocardial ischemia/reperfusion injury, Myocardial injuryAbstract
Following myocardial infarction, it is crucial to promptly restore blood and nutrient supply to the ischemic area; however, reperfusion after interrupted blood flow often leads to more severe myocardial damage, known as myocardial ischemia/reperfusion injury (MIRI). The pathological mechanism of MIRI remains incompletely understood, and there are limited therapeutic measures available for practical clinical application. Therefore, further research is needed to explore additional interventions aimed at improving myocardial injury and cardiac function. Adipocytokines are secreted proteins produced by adipose tissue that directly impact MIRI through autocrine, paracrine, or endocrine modes on nearby or remote organs. This review provides a concise overview of the cardioprotective effects and potential mechanisms of adipocytokines in MIRI.
References
Task Force Members, Thygesen K, Alpert J S, et al. Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction [J]. European Heart Journal, 2007, 28(20): 2525-2538.
Yellon D M, Hausenloy D J. Myocardial Reperfusion Injury [J]. The New England Journal of Medicine, 2007, 357(11):1121-1135.
Verma S, Fedak P W M, Weisel R D, et al. Fundamentals of Reperfusion Injury for the Clinical Cardiologist [J]. Circulation, 2002, 105(20): 2332-2336.
Yellon D M. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? [J]. Heart, 2000, 83(4): 381-387.
Kalogeris T, Baines C P, Krenz M, et al. Cell Biology of Ischemia/Reperfusion Injury [M/OL]//International Review of Cell and Molecular Biology. Elsevier, 2012, 229-317 [2023-01-06].
Kershaw E E, Flier J S. Adipose Tissue as an Endocrine Organ [J]. The Journal of Clinical Endocrinology & Metabolism, 2004, 89(6): 2548-2556.
Zorena K, Jachimowicz-Duda O, Ślęzak D, et al. Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications [J]. International Journal of Molecular Sciences, 2020, 21(10): 3570.
Fasshauer M, Blüher M. Adipokines in health and disease [J]. Trends in Pharmacological Sciences, 2015, 36(7): 461-470.
Nakamura K, Fuster J J, Walsh K. Adipokines: A link between obesity and cardiovascular disease [J]. Journal of Cardiology, 2014, 63(4): 250-259.
Ouwens D M, Sell H, Greulich S, et al. The role of epicardial and perivascular adipose tissue in the pathophysiology of cardiovascular disease [J]. Journal of Cellular and Molecular Medicine, 2010, 14(9): 2223-2234.
Jun Y, Xiao T, Guoyong Y, et al. Recombinant globular adiponectin inhibits lipid deposition by p38 MAPK/ATF-2 and TOR/p70 S6 kinase pathways in chicken adipocytes [J]. Biochemistry and Cell Biology, 2014, 92(1): 53-60.
Tian X-Q, Yang Y-J, Li Q, et al. Globular Adiponectin Inhibits the Apoptosis of Mesenchymal Stem Cells Induced by Hypoxia and Serum Deprivation via the AdipoR1-Mediated Pathway [J]. Cellular Physiology and Biochemistry, 2016, 38(3): 909-925.
Kim Y, Cho J Y, Oh S W, et al. Globular adiponectin acts as a melanogenic signal in human epidermal melanocytes [J]. British Journal of Dermatology, 2018, 179(3): 689-701.
Onay-Besikci A, Altarejos J Y, Lopaschuk G D. gAd-globular Head Domain of Adiponectin Increases Fatty Acid Oxidation in Newborn Rabbit Hearts [J]. Journal of Biological Chemistry, 2004, 279(43): 44320-44326.
Han X, Wu Y, Liu X, et al. Adiponectin improves coronary no-reflow injury by protecting the endothelium in rats with type 2 diabetes mellitus [J]. Bioscience Reports, 2017, 37(4): BSR20170282.
Chandran M, Phillips S A, Ciaraldi T, et al. Adiponectin: More Than Just Another Fat Cell Hormone? [J]. Diabetes Care, 2003, 26(8): 2442-2450.
Han W, Yang S, Xiao H, et al. Role of Adiponectin in Cardiovascular Diseases Related to Glucose and Lipid Metabolism Disorders [J]. International Journal of Molecular Sciences, 2022, 23(24): 15627.
Cao C, Liu H, Li W, et al. Role of adiponectin in diabetes myocardial ischemia-reperfusion injury and ischemic postconditioning [J]. Acta Cirúrgica Brasileira, 2020, 35(1): e202000107.
Zhu D, Zhang Z, Zhao J, et al. Targeting Adiponectin Receptor 1 Phosphorylation Against Ischemic Heart Failure [J/OL]. Circulation Research, 2022, 131(2) [2023-07-11].
Huang L, Ding L, Yu S, et al. Propofol postconditioning alleviates diabetic myocardial ischemia‑reperfusion injury via the miR‑200c‑3p/AdipoR2/STAT3 signaling pathway [J]. Molecular Medicine Reports, 2022, 25(4): 137.
Potenza M A, Sgarra L, Nacci C, et al. Activation of AMPK/SIRT1 axis is required for adiponectin-mediated preconditioning on myocardial ischemia-reperfusion (I/R) injury in rats [J]. PLOS ONE, 2019, 14(1): e0210654.
Ren C, Yi W, Jiang B, et al. Diminished AdipoR1/ APPL1 Interaction Mediates Reduced Cardioprotective Actions of Adiponectin against Myocardial Ischemia/Reperfusion Injury in Type-2 Diabetic Mice [J]. Stem Cells International, 2023, 2023: 1-8.
Zhu Q, Li H, Xie X, et al. Adiponectin Facilitates Postconditioning Cardioprotection through Both AMPK-Dependent Nuclear and AMPK-Independent Mitochondrial STAT3 Activation [J]. Oxidative Medicine and Cellular Longevity, 2020, 2020: 1-17.
Zhu K, Guo J, Yu X, et al. Polypeptide Globular Adiponectin Ameliorates Hypoxia/Reoxygenation- Induced Cardiomyocyte Injury by Inhibiting Both Apoptosis and Necroptosis [J]. Journal of Immunology Research, 2021, 2021: 1-14.
Guo J, Zhu K, Li Z, et al. Adiponectin Protects Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury by Suppressing Autophagy [J]. Journal of Immunology Research, 2022, 2022: 1-11.
Dakroub A, A. Nasser S, Younis N, et al. Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders [J]. Cells, 2020, 9(11): 2444.
Samal B, Sun Y, Stearns G, et al. Cloning and Characterization of the cDNA Encoding a Novel Human Pre-B-Cell Colony-Enhancing Factor [J]. 1994, 14.
Dakroub A, Nasser S A, Kobeissy F, et al. Visfatin: An emerging adipocytokine bridging the gap in the evolution of cardiovascular diseases [J]. Journal of Cellular Physiology, 2021, 236(9): 6282-6296.
Avesta L, Doustkami H, Zamani B, et al. Association of plasma visfatin with epicardial fat thickness and severity of coronary artery diseases in patients with acute myocardial infarction and stable angina pectoris [J/OL]. ARYA Atherosclerosis Journal, 2022, 18(July) [2024-02-28].
Zhang H, Lei D, Zhang M, et al. Correlations of visfatin with severity of acute myocardial infarction, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention [J]. Journal of Medical Biochemistry, 2023, 42(4): 650-657.
Lim S Y, Davidson S M, Paramanathan A J, et al. The novel adipocytokine visfatin exerts direct cardioprotective effects [J]. Journal of Cellular and Molecular Medicine, 2008, 12(4): 1395-1403.
Ju J, Li X-M, Zhao X-M, et al. Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/ reperfusion injury by interacting with NAMPT [J]. Journal of Biomedical Science, 2023, 30(1): 45.
Yamamoto T, Byun J, Zhai P, et al. Nicotinamide Mononucleotide, an Intermediate of NAD+ Synthesis, Protects the Heart from Ischemia and Reperfusion [J]. PLoS ONE, 2014, 9(6): e98972.
Montecucco F, Bauer I, Braunersreuther V, et al. Inhibition of Nicotinamide Phosphoribosyltransferase Reduces Neutrophil-Mediated Injury in Myocardial Infarction [J]. Antioxidants & Redox Signaling, 2013, 18(6): 630-641.
Xin BR, Li P, Liu XL, Zhang XF. Visfatin relieves myocardial ischemia-reperfusion injury through activation of PI3K/Akt/HSP70 signaling axis [J]. European review for medical and pharmacological sciences, 2020, 24(20):10779-10789.
Tur J, Badole S L, Manickam R, et al. Cardioprotective Effects of 1-(3, 6-Dibromo-carbazol-9-yl)-3- Phenylamino-Propan-2-Ol in Diabetic Hearts via Nicotinamide Phosphoribosyltransferase Activation [J]. Journal of Pharmacology and Experimental Therapeutics, 2022, 382(2): 233-245.
Kawano J, Arora R. The Role of Adiponectin in Obesity, Diabetes, and Cardiovascular Disease [J]. Journal of the CardioMetabolic Syndrome, 2009, 4(1): 44-49.
Seldin M M, Tan S Y, Wong G W. Metabolic function of the CTRP family of hormones [J]. Reviews in Endocrine and Metabolic Disorders, 2014, 15(2): 111-123.
Su H, Yuan Y, Wang X-M, et al. Inhibition of CTRP9, a novel and cardiac-abundantly expressed cell survival molecule, by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice [J]. Basic Research in Cardiology, 2013, 108(1): 315.
Liu M, Li W, Wang H, et al. CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post‐Myocardial Infarction Rats [J]. Journal of the American Heart Association, 2019, 8(21): e013133.
Liu M, Yin L, Li W, et al. C1q/TNF‐related protein‐9 promotes macrophage polarization and improves cardiac dysfunction after myocardial infarction [J]. Journal of Cellular Physiology, 2019, 234(10): 18731-18747.
Yan W, Guo Y, Tao L, et al. C1q/Tumor Necrosis Factor–Related Protein-9 Regulates the Fate of Implanted Mesenchymal Stem Cells and Mobilizes Their Protective Effects Against Ischemic Heart Injury via Multiple Novel Signaling Pathways [J]. Circulation, 2017, 136(22): 2162-2177.
Zhao D, Feng P, Sun Y, et al. Cardiac-derived CTRP9 protects against myocardial ischemia/reperfusion injury via calreticulin-dependent inhibition of apoptosis [J]. Cell Death & Disease, 2018, 9(7): 723.
Klagsbrun M. The fibroblast growth factor family: Structural and biological properties [J]. Progress in Growth Factor Research, 1989, 1(4): 207-235.
Bookout A L, De Groot M H M, Owen B M, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system [J]. Nature Medicine, 2013, 19(9): 1147-1152.
Cong W-T, Ling J, Tian H-S, et al. Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia–reperfusion injury [J]. Canadian Journal of Physiology and Pharmacology, 2013, 91(11): 973-984.
Hu S, Cao S, Tong Z, et al. FGF21 protects myocardial ischemia-reperfusion injury through reduction of miR-145-mediated autophagy [J]. American journal of translational research, 10(11), 3677–3688.
Ren Z, Xiao W, Zeng Y, et al. Fibroblast growth factor-21 alleviates hypoxia/reoxygenation injury in H9c2 cardiomyocytes by promoting autophagic flux [J/OL]. International Journal of Molecular Medicine, 2019 [2023-01-02].
Hu S, Cao S, Liu J. Role of angiopoietin-2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion-induced injury in H9c2 cardiomyocytes [J]. Experimental and Therapeutic Medicine, 2017, 14(1): 771-779.
Sun M, Jin L, Bai Y, et al. Fibroblast growth factor 21 protects against pathological cardiac remodeling by modulating galectin‐3 expression [J]. Journal of Cellular Biochemistry, 2019, 120(12): 19529-19540.
Moon H, Choi J-W, Song B-W, et al. Brite Adipocyte FGF21 Attenuates Cardiac Ischemia/Reperfusion Injury in Rat Hearts by Modulating NRF2 [J]. Cells, 2022, 11(3): 567.
Liu S Q, Roberts D, Kharitonenkov A, et al. Endocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue [J]. Scientific Reports, 2013, 3(1): 2767.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Shasha Chen, Yanjie Guo
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
